Ascendis Pharma A/S (NASDAQ:ASND) is ARS Investment Partners LLC's 7th Largest Position

ARS Investment Partners LLC grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 265,480 shares of the biotechnology company's stock after purchasing an additional 2,369 shares during the period. Ascendis Pharma A/S makes up approximately 3.3% of ARS Investment Partners LLC's holdings, making the stock its 7th largest position. ARS Investment Partners LLC owned approximately 0.44% of Ascendis Pharma A/S worth $36,549,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $30,000. GAMMA Investing LLC boosted its stake in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 214 shares during the last quarter. Signaturefd LLC increased its holdings in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after purchasing an additional 80 shares in the last quarter. Pursue Wealth Partners LLC purchased a new position in shares of Ascendis Pharma A/S in the third quarter worth $217,000. Finally, Rhumbline Advisers lifted its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after purchasing an additional 143 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $2.93 during trading on Tuesday, hitting $131.06. The company had a trading volume of 631,765 shares, compared to its average volume of 455,055. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The firm has a market capitalization of $7.95 billion, a P/E ratio of -16.22 and a beta of 0.65. The stock has a 50 day simple moving average of $133.19 and a 200 day simple moving average of $133.40.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. reduced their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating for the company in a report on Wednesday, October 23rd. TD Cowen reduced their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Bank of America increased their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 target price for the company. Finally, Wedbush reissued an "outperform" rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and an average price target of $192.07.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.